Art. -Nr.: HY-W040055

Neopterin

(Synonyms: D-(+)-Neopterin; D-erythro-Neopterin)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Neopterin is an immune system activator metabolized by GTP and can be produced by activated macrophages. Neopterin has the potential to resist vascular inflammation and atherosclerosis. Neopterin inhibits the phosphorylation of NF-κB and promotes the expression of PPAR-γ, thereby suppressing the inflammatory response of vascular endothelial cells, reducing the formation of macrophage foam cells, and regulating the migration and proliferation of vascular smooth muscle cells. Neopterin can be used in research fields such as cardiovascular diseases (such as atherosclerosis), inflammation-related diseases and tumor immunomonitoring.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 2009-64-5
Formel: C₉H₁₁N₅O₄
Molecular Weight:253.21

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Neopterin Chemical Structure

CAS. Nr.: 2009-64-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Human Endogenous Metabolite

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle Raf Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle PPAR Isoform-spezifische Produkte anzeigen :

Alle Src Isoform-spezifische Produkte anzeigen :

In Vitro

Neopterin (200 nM; 4-48 h) inhibits cell proliferation, reduces the mRNA and protein expression of inflammatory factors such as MCP-1, ICAM-1, and VCAM-1 induced by TNF-α, and reduces monocyte adhesion in human aortic endothelial cells (HAECs) and human umbilical vein endothelial cells (HUVECs)^[1].
Neopterin (200 nM; 7 d+19 h) inhibits oxidized low-density lipoprotein (oxLDL)-induced foam cell formation in human monocyte-derived macrophages (HMDMs), downregulates CD36 expression, upregulates ABCA1, ABCG1, and LXR-α protein levels, and promotes cholesterol efflux^[1].
Neopterin (200 nM; 24-48 h) inhibits angiotensin II-induced cell migration and proliferation, downregulates the c-Src/Raf-1/ERK1/2 signaling pathway, and upregulates the expression of fibronectin, MMP-2, and TIMP-2 proteins in human aortic smooth muscle cells (HASMCs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human aortic endothelial cells (HAECs), human umbilical vein endothelial cells (HUVECs), human aortic smooth muscle cells (HASMCs)
Concentration:

5-200 nM
Incubation Time:

48 h
Result:

Significantly suppressed proliferation in HAECs and HUVECs in a concentration-dependent manner, with maximal inhibition at 200 nM.
Reduced cell viability, with the most pronounced effect at 200 nM in HASMCs.

In Vivo

Neopterin (1.2 μmol/kg; ip; once a day; 4 weeks) significantly slows the progression of aortic atherosclerotic lesions, reduces plaque area and monocyte/macrophage and CD8+ T cell infiltration, and reduces the content of vascular smooth muscle cells and plasma PTX-3 levels in apolipoprotein E-deficient (Apoe-) mice[1].
Neopterin (0.4-4.0 mg/kg; iv; single dose, tested for 21 days) causes a decrease in the number of bone marrow erythroid progenitors (BFU-E, CFU-E) and an increase in the number of myeloid progenitors (CFU-GM) in young mice in the aging-associated stromal cell damage model of male senescence-accelerated mice, while the number of erythroid progenitors decreases in aged mice, but serum erythropoietin (Epo) concentrations did not decrease.^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 Apoe^- mice (27-29 g, 17-21 weeks old) with diet-induced atherosclerosis^[1]
Dosage:

1.2 μmol/kg
Administration:

Intraperitoneal injection daily for 4 weeks
Result:

Aortic atherosclerotic lesion area and cross-sectional plaque size at the aortic root were reduced by 35% and 17%, respectively, compared to vehicle-treated controls.
Immunohistochemistry showed decreased infiltration of monocyte/macrophages (MOMA-2⁺ cells) and CD8⁺ T cells in atheromatous plaques.
Vascular smooth muscle cell (α-SMA⁺) content and expression of pro-inflammatory markers MCP-1 and PTX-3 in plaques were significantly lower in neopterin-treated mice.
Plasma PTX-3 levels, a marker of plaque instability, were reduced by 30% compared to controls.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 2009-64-5
Appearance Solid
Molecular Weight 253.21
Formel C₉H₁₁N₅O₄
Color White to off-white
SMILES

OC1=C2C(N=CC([C@H](O)[C@H](O)CO)=N2)=NC(N)=N1
Synonyms

D-(+)-Neopterin; D-erythro-Neopterin
Structure Classification
- Others
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Chem Biol Interact

Cinnamic acid induces neurodevelopmental defects via PPARγ signaling in zebrafish. [Abstract]

2026 Mar 25:427:111929. PMID: 41548734

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 4.17 mg/mL (16.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9493 mL

19.7465 mL

39.4929 mL

5 mM

0.7899 mL

3.9493 mL

7.8986 mL

10 mM

0.3949 mL

1.9746 mL

3.9493 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shirai R, et al. Neopterin Counters Vascular Inflammation and Atherosclerosis. J Am Heart Assoc. 2018 Feb 2;7(3):e007359. [Content Brief]

[2]. Aisaki K, et al. Neopterin, inflammation-associated product, prolongs erythropoiesis suppression in aged SAMP1 mice due to senescent stromal-cell impairment. Exp Biol Med (Maywood). 2012 Mar;237(3):279-86. [Content Brief]

[3]. Fuchs D, et al. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci. 1992;29(3-4):307-41. [Content Brief]

[4]. Sucher R, et al. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010 Jan 1;287(1):13-22. [Content Brief]

[5]. Murr C, et al. Neopterin as a Marker for Immune System Activation. Current Drug Metabolism [01 Apr 2002, 3(2):175-187].

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9493 mL	19.7465 mL	39.4929 mL	98.7323 mL
	5 mM	0.7899 mL	3.9493 mL	7.8986 mL	19.7465 mL
	10 mM	0.3949 mL	1.9746 mL	3.9493 mL	9.8732 mL
	15 mM	0.2633 mL	1.3164 mL	2.6329 mL	6.5822 mL

Keywords

Neopterin

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Neopterin

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Animal-Sourced Natural Product Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Neopterin

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle Raf Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle PPAR Isoform-spezifische Produkte anzeigen

Alle Src Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs